Investigating a new treatment for Alzheimer's disease
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Alzheimer's Disease
This study is testing a new pill that aims to help people with Alzheimer's by blocking a harmful substance in the brain, with the hope of making daily life easier and improving memory, while keeping an eye on how safe it is for those who take it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10690672 on NIH RePORTER |
What this research studies
This research focuses on a novel oral medication designed to target a specific receptor involved in Alzheimer's disease. By blocking the harmful effects of amyloid beta accumulation on brain cells, the treatment aims to improve cognitive function and daily living activities for patients. The study will assess the safety and tolerability of this medication in patients with Alzheimer's, with the hope of slowing or reversing disease progression. Participants will be monitored for any side effects and improvements in their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with mild to moderate Alzheimer's disease.
Not a fit: Patients with advanced Alzheimer's disease or other forms of dementia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that significantly improves the quality of life for individuals with Alzheimer's disease.
How similar studies have performed: Previous research has shown promise with similar approaches targeting the mGluR5 receptor in preclinical models, indicating potential for success in human trials.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Mecca, Adam Peter — Yale University
- Study coordinator: Mecca, Adam Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.